Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial

J. Harding, J. Cleary, G. Shapiro, I. Braña, V. Moreno, D. Quinn, M. Borad, S. Loi, I. Spanggaard, S. Stemmer, M. Dujka, R. Cutler, F. Xu, L. Eli, S. Macia, A. Lalani, R. Bryce, F. Meric Bernstam, D. Solit, D. HymanS. Piha-Paul

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)iv127
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume30
DOIs
StatePublished - Jul 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Harding, J., Cleary, J., Shapiro, G., Braña, I., Moreno, V., Quinn, D., Borad, M., Loi, S., Spanggaard, I., Stemmer, S., Dujka, M., Cutler, R., Xu, F., Eli, L., Macia, S., Lalani, A., Bryce, R., Bernstam, F. M., Solit, D., ... Piha-Paul, S. (2019). Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv127. https://doi.org/10.1093/annonc/mdz154.004